Vor Biopharma prices $115.8M combined stock offering and private placement at $4.30/share

Vor Biopharma Inc.

15.3M shares sold in underwritten offering for gross $65.8M; 11.6M shares in private placement to RA Capital for $50M.
Net proceeds from underwritten offering estimated at $61.4M after discounts and expenses; private placement net not disclosed.
Proceeds to fund clinical pipeline development and working capital; closings expected December 9, 2022.
Private placement shares are unregistered; company must file resale registration by Jan 8, 2023 or issue warrants by Dec 31, 2022.
Underwriters: Evercore, Stifel, Oppenheimer; RA Capital is company's largest stockholder.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vor Biopharma Inc. entered into Securities Purchase Agreement with RA Capital Healthcare Fund, L.P. valued at approximately $50.0 million (effective 2022-12-07).

Action: entry
Agreement: equity purchase
Counterparty: RA Capital Healthcare Fund, L.P.
Value: approximately $50.0 million
Effective: 2022-12-07

Exact text from the filing

On December 7, 2022, the Company entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with RA Capital Healthcare Fund, L.P. (“ RA Capital ”). Pursuant to the Securities Purchase Agreement, RA Capital agreed to purchase, and the Company agreed to issue to RA Capital 11,627,907 shares of Common Stock at a price of $4.30 per share (the “ Private Placement ”). The total purchase price shall be equal to approximately $50.0 million.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vor Biopharma Inc. entered into Underwriting Agreement with Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated valued at approximately $61.4 million (effective 2022-12-07).

Action: entry
Agreement: underwriting
Counterparty: Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated
Value: approximately $61.4 million
Effective: 2022-12-07

Exact text from the filing

On December 7, 2022, Vor Biopharma Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “ Underwriters ”), relating to an offering (the “ Offering ”) of 15,302,267 shares (the “ Shares ”) of the Company’s common stock

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-300211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.